Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Mutti

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Occupational and Environmental Medicine|March 27, 2017
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individualsChiara De Santi, Perla Pucci, Alessandra Bonotti, et al.
Translational Lung Cancer Research|January 25, 2021
Immunotherapy beyond progression in patients with advanced non-small cell lung cancerXiangwei Ge, Zhibo Zhang, Sujie Zhang, et al.
Cancers|June 2, 2021
Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility StudyGabriele Moretti, Paolo Aretini, Francesca Lessi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
La Radiologia Medica|February 14, 2023
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a reviewValerio Nardone, Caterina Romeo, Emma D'Ippolito, et al.
Frontiers in Oncology|October 3, 2022
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approachAntonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, et al.
Cells|August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced PneumonitisPierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Life (Basel, Switzerland)|November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional AnalysisValerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Frontiers in Endocrinology|March 14, 2019
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?Anne-Marie Baird, David Easty, Monika Jarzabek, et al.
The European Respiratory Journal|May 27, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaArnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Occupational and Environmental Medicine|March 27, 2017
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individualsChiara De Santi, Perla Pucci, Alessandra Bonotti, et al.
Translational Lung Cancer Research|January 25, 2021
Immunotherapy beyond progression in patients with advanced non-small cell lung cancerXiangwei Ge, Zhibo Zhang, Sujie Zhang, et al.
Cancers|June 2, 2021
Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility StudyGabriele Moretti, Paolo Aretini, Francesca Lessi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
La Radiologia Medica|February 14, 2023
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a reviewValerio Nardone, Caterina Romeo, Emma D'Ippolito, et al.
Frontiers in Oncology|October 3, 2022
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approachAntonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, et al.
Cells|August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced PneumonitisPierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Life (Basel, Switzerland)|November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional AnalysisValerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Frontiers in Endocrinology|March 14, 2019
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?Anne-Marie Baird, David Easty, Monika Jarzabek, et al.
The European Respiratory Journal|May 27, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaArnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, et al.
Pageof 13